CytoDyn Inc. (CYDY) Sees Promising HIV Treatment Trial Results, Gets Go-Ahead to Raise Dosage
Response rate to PRO 140 rose from 40 percent at 350mg dose to 70 percent at 525mg Institutional Review Board (IRB) allows trials of viral-entry inhibitor to continue at 700mg dose PRO 140 is an FDA fast-track candidate Following clinical trial results showing that its new anti-HIV treatment is more effective at higher dosages, biotechnology company CytoDyn Inc. (OTCQB: CYDY) is set to give trial participants an increased weekly dose of PRO 140 (http://nnw.fm/3g2Np). The latest round of trial results showed that the response rate among trial participants treated with the viral-entry inhibitor rose from 40 percent at a 350mg…







